Fulcrum Therapeutics (FULC) Equity Average: 2019-2025
Historic Equity Average for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $206.4 million.
- Fulcrum Therapeutics' Equity Average fell 22.28% to $206.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.4 million, marking a year-over-year decrease of 22.28%. This contributed to the annual value of $239.1 million for FY2024, which is 10.16% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Equity Average stood at $206.4 million for Q3 2025, which was down 6.80% from $221.4 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Equity Average registered a high of $285.8 million during Q2 2023, and its lowest value of $111.5 million during Q1 2021.
- For the 3-year period, Fulcrum Therapeutics' Equity Average averaged around $244.7 million, with its median value being $245.3 million (2023).
- Its Equity Average has fluctuated over the past 5 years, first soared by 120.89% in 2021, then decreased by 22.28% in 2025.
- Fulcrum Therapeutics' Equity Average (Quarterly) stood at $221.1 million in 2021, then decreased by 4.93% to $210.2 million in 2022, then grew by 16.72% to $245.3 million in 2023, then increased by 1.97% to $250.2 million in 2024, then decreased by 22.28% to $206.4 million in 2025.
- Its Equity Average stands at $206.4 million for Q3 2025, versus $221.4 million for Q2 2025 and $235.8 million for Q1 2025.